PCSK9 and homozygous familial hypercholesterolemia: In recent years, the PCSK9 inhibitor evolocumab, the small interfering RNA cholesterol-lowering drug inclisiran, and two innovative oral fixed-dose combinations—ezetimibe/atorvastatin (II) and rosuvastatin/ezetimibe (I)—have been approved for the treatment of patients with HoFH.